The role of the RhoA/rho-kinase pathway in pulmonary hypertension

Current Drug Discovery Technologies

Volumn 6, Issue 1, 2009, Pages 59-71

  Nossaman, Bobby D ^a,b   Kadowitz, Philip J ^b  

^a OCHSNER MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Fasudil; HA 1077; Inhibitors pharmacology; Intracellular signaling peptides and proteins; Muscle; Protein kinases; Pulmonary hypertension; Pulmonary vascular bed; Rhoa rho kinase pathway; Signal transduction; Smooth; Systemic vascular bed; Vascular; Y 27632

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CALCIUM CHANNEL; FASUDIL; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

BLOOD VESSEL TONE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE CONTRACTION; VASOCONSTRICTION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION, PULMONARY; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; VASOCONSTRICTION; VASODILATION;

EID: 62249102189     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309787581057     Document Type: Review

References (363)

1. Vogel R.A.: Heads and hearts: the endothelial connection.[comment]. Circulation 107(22), 2766, (2003).
2. Christ G., Wingard C.: Calcium sensitization as a pharmacological target in vascular smooth-muscle regulation. Curr. Opin. Investig. Drugs. 6(9), 920, (2005).
3. Virdis A., Schiffrin E.L.: Vascular inflammation: a role in vascular disease in hypertension? Curr. Opin. Nephrol. Hypertens. 12(2), 181, (2003).
4. Endemann D.H., Schiffrin E.L.: Endothelial dysfunction. J. Am. Soc. Nephrol. 15(8), 1983, (2004).
5. Ogita H., Liao J.: Endothelial function and oxidative stress. Endothelium 11(2), 123, (2004).
6. Nossaman B.D., Gur S., Kadowitz P.J.: Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction. Curr. Gene Ther. 7(2), 131, (2007).
7. Lüscher T.F., Barton M.: Biology of the endothelium. Clin. Cardiol. 20(11 Suppl 2), II, (1997).
8. Van Eyk J.E., Arrell D.K., Foster D.B., Strauss J.D., Heinonen T.Y., Furmaniak-Kazmierczak E., Côté G.P., Mak A.S.: Different molecular mechanisms for Rho family GTPase-dependent, Ca2+-independent contraction of smooth muscle. J. Biol. Chem. 273(36), 23433, (1998).
9. Somlyo A.P., Somlyo A.V.: Signal transduction and regulation in smooth muscle. Nature 372(6503), 231, (1994).
10. Stull J.T., Gallagher P.J., Herring B.P., Kamm K.E.: Vascular smooth muscle contractile elements. Cellular regulation. Hypertension 17(6), 723, (1991).
11. Somlyo A.P., Somlyo A.V.: From pharmacomechanical coupling to G-proteins and myosin phosphatase. Acta Physiol. Scand. 164(4), 437, (1998).
12. Somlyo A.P., Somlyo A.V.: Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. 522 (Pt 2), 177, (2000).
13. Somlyo A.P., Somlyo A.V.: Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 83(4), 1325, (2003).
14. Schubert R., Lidington D., Bolz S.-S.: The emerging role of Ca2+ sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc. Res. 77(1), 8, (2008).
15. Kureishi Y., Kobayashi S., Amano M., Kimura K., Kanaide H., Nakano T., Kaibuchi K., Ito M.: Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J. Biol. Chem. 272(19), 12257, (1997).
16. Karaki H., Ozaki H., Hori M., Mitsui-Saito M., Amano K.-I., Harada K.-I., Miyamoto S., Nakazawa H., et al.: Calcium Movements, Distribution, and Functions in Smooth Muscle. Pharmacol. Rev. 49(2), 157, (1997).
17. Kamm K.E., Stull J.T.: The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Ann. Rev. Pharmacol. Toxicol. 25(1), 593, (1985).
18. McFadzean I., Gibson A.: The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br. J. Pharmacol. 135(1), 1, (2002).
19. Akata T.: Cellular and molecular mechanisms regulating vascular tone. Part 2: regulatory mechanisms modulating Ca(2+) mobilization and/or myofilament Ca (2+) sensitivity in vascular smooth muscle cells. J. Anesth. 21(2), 232, (2007).
20. Ward J.P.T., Knock G.A., Snetkov V.A., Aaronson P.I.: Protein kinases in vascular smooth muscle tone--role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Pharmacol. Ther. 104(3), 207, (2004).
21. Abdel-Latif A.A.: Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. Exp. Biol. Med. (Maywood) 226(3), 153, (2001).
22. Sanders L.C., Matsumura F., Bokoch G.M., de L.P.: Inhibition of myosin light chain kinase by p21-activated kinase. Science 283(5410), 2083, (1999).
23. Shimokawa H., Takeshita A.: Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 25(9), 1767, (2005).
24. Kumar R., Singh V.P., Baker K.M.: Kinase inhibitors for cardiovascular disease. J. Mol. Cell Cardiol. 42(1), 1, (2007).
25. Cogolludo A., Moreno L., Villamor E.: Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. Pharmacology 79(2), 65, (2007).
26. Cogolludo A., Pérez-Vizcaíno F., Tamargo J.: New insights in the pharmacological therapy of arterial hypertension. Curr. Opin. Nephrol. Hypertens. 14(5), 423, (2005).
27. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., Gibbs S., Lebrec D., et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43(12 Suppl S), 5S, (2004).
28. Widlitz A., Barst R.J.: Pulmonary arterial hypertension in children. Eur. Respir. J. 21(1), 155, (2003).
29. Raiesdana A., Loscalzo J.: Pulmonary arterial hypertension. Ann. Med. 38(2), 95, (2006).
30. Rich S., Rubin L., Walker A.M., Schneeweiss S., Abenhaim L.: Anorexigens and pulmonary hypertension in the United States*: Results from the surveillance of North American pulmonary hypertension. Chest 117(3), 870, (2000).
31. Rubin L.J.M., Badesch D.B.M.: Evaluation and management of the patient with pulmonary arterial hypertension. Ann. Intern. Med. 143(4), 282, (2005).
32. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., Gibbs S., Lebree D., et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43(12 Suppl S), 5S, (2004).
33. Raiesdana A., Loscalzo J.: Pulmonary arterial hypertension. Ann. Med. 38(2), 95, (2006).
34. Chin K.M., Kim N.H.S., Rubin L.J.: The right ventricle in pulmonary hypertension. Coron. Artery Dis. 16(1), 13, (2005).
35. Michelakis E.D., Weir E.K.: The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels. Clin. Chest Med. 22(3), 419, (2001).
36. Kaul T.K., Fields B.L.: Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. Cardiovasc. Surg. 8(1), 1, (2000).
37. De Backer T.L., Smedema J.P., Carlier S.G.: Current management of primary pulmonary hypertension. Biodrugs 15(12), 801, (2001).
38. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., Gaine S.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl S), 40S, (2004).
39. McCrory D.C., Lewis S.Z.: Methodology and grading for pulmonary hypertension evidence review and guideline development. Chest 126(1 Suppl), 11S, (2004).
40. Hoeper M.M.: Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 65(10), 1337, (2005).
41. Galie N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., Olschewski H., Peacock A., et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. 25(24), 2243, (2004).
42. Tawara S., Shimokawa H.: Progress of the Study of Rho-kinase and Future Perspective of the Inhibitor. Yakugaku Zasshi 127(3), 501, (2007).
43. Morrell E.D., Tsai B.M., Crisostomo P.R., Wang M., Markel T.A., Lillemoe K.D., Meldrum D.R.: Therapeutic concepts for hypoxic pulmonary vasoconstriction involving ion regulation and the smooth muscle contractile apparatus. J. Mol. Cell Cardiol. 40(6), 751, (2006).
44. Morrell E.D., Tsai B.M., Crisostomo P.R., Hammoud Z.T., Meldrum D.R.: Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. Shock 25(3), 214, (2006).
45. Doggrell S.A.: Rho-kinase inhibitors show promise in pulmonary hypertension. Expert Opin. Investig. Drugs 14(9), 1157, (2005).
46. Jeffery T.K., Morrell N.W.: Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog. Cardiovasc. Dis. 45(3), 173, (2002).
47. Xing X.-Q., Gan Y., Wu S.-J., Chen P., Zhou R., Xiang X.-D.: Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension. Drug News Perspect. 19(9), 517, (2006).
48. Ishikura K., Yamada N., Ito M., Ota S., Nakamura M., Isaka N., Nakano T.: Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ. J. 70(2), 174, (2006).
49. Fukumoto Y., Matoba T., Ito A., Tanaka H., Kishi T., Hayashidani S., Abe K., Takeshita A., et al.: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91(3), 391, (2005).
50. Hyvelin J.-M., Howell K., Nichol A., Costello C.M., Preston R.J., McLoughlin P.: Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ. Res. 97(2), 185, (2005).
51. Li F.-H., Xia W., Li A.-W., Zhao C.-F., Sun R.-P.: Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin. Med. J. (Engl) 120(1), 22, (2007).
52. Parker T.A., Roe G., Grover T.R., Abman S.H.: Rho kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am. J. Physiol. Lung Cell Mol. Physiol. 291(5), L976, (2006).
53. Nagaoka T., Gebb S.A., Karoor V., Homma N., Morris K.G., McMurtry I.F., Oka M.: Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J. Appl. Physiol. 100(3), 996, (2006).
54. Aaronson P.I., Robertson T.P., Knock G.A., Becker S., Lewis T.H., Snetkov V., Ward J.P.T.: Hypoxic pulmonary vasoconstriction: mechanisms and controversies. J. Physiol. 570(Pt 1), 53, (2006).
55. Nagaoka T., Morio Y., Casanova N., Bauer N., Gebb S., McMurtry I., Oka M.: Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am. J. Physiol. Lung Cell Mol. Physiol. 287(4), L665, (2004).
56. Michelakis E.D., Thébaud B., Weir E.K., Archer S.L.: Hypoxic pulmonary vasoconstriction: redox regulation of O2-sensitive K+ channels by a mitochondrial O2-sensor in resistance artery smooth muscle cells. J. Mol. Cell Cardiol. 37(6), 1119, (2004).
57. Feng C.J., Cheng D.Y., Kaye A.D., Kadowitz P.J., Nossaman B.D.: Influence of N omega-nitro-L-arginine methyl ester, LY83583, glybenclamide and L158809 on pulmonary circulation. Eur. J. Pharmacol. 263(1-2), 133, (1994).
58. Niiro N., Koga Y., Ikebe M.: Agonist-induced changes in the phosphorylation of the myosin- binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem. J. 369(Pt 1), 117, (2003).
59. Kitazawa T., Eto M., Woodsome T.P., Khalequzzaman M.: Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle. J. Physiol. 546(Pt 3), 879, (2003).
60. Robertson T.P., Dipp M., Ward J.P., Aaronson P.I., Evans A.M.: Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br. J. Pharmacol. 131(1), 5, (2000).
61. Wang Z., Jin N., Ganguli S., Swartz D.R., Li L., Rhoades R.A.: Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am. J. Respir. Cell Mol. Biol. 25(5), 628, (2001).
62. Jernigan N.L., Walker B.R., Resta T.C.: Chronic hypoxia augments protein kinase G-mediated Ca2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 287(6), L1220, (2004).
63. Fagan K.A., Oka M., Bauer N.R., Gebb S.A., Ivy D.D., Morris K.G., McMurtry I.F.: Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 287(4), L656, (2004).
64. Roos C.M., Frank D.U., Xue C., Johns R.A., Rich G.F.: Chronic inhaled nitric oxide: effects on pulmonary vascular endothelial function and pathology in rats. J. Appl. Physiol. 80(1), 252, (1996).
65. Broughton B.R.S., Walker B.R., Resta T.C.: Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries. Am. J. Physiol. Lung Cell Mol. Physiol. 294(4), L797, (2008).
66. Resta T.C., Chicoine L.G., Omdahl J.L., Walker B.R.: Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 276(2), H699, (1999).
67. Everett A.D., Le Cras T.D., Xue C., Johns R.A.: eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am. J. Physiol. Lung Cell Mol. Physiol. 274(6 Pt 1), L1058, (1998).
68. Le Cras T.D., Xue C., Rengasamy A., Johns R.A.: Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am. J. Physiol. Lung Cell Mol. Physiol. 270(1 Pt 1), L164, (1996).
69. Xue C., Rengasamy A., Le Cras T.D., Koberna P.A., Dailey G.C., Johns R.A.: Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 267(6 Pt 1), L667, (1994).
70. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., Hattori T., Nakashima Y., et al.: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 94(3), 385, (2004).
71. Langleben D., Szarek J.L., Coflesky J.T., Jones R.C., Reid L.M., Evans J.N.: Altered artery mechanics and structure in monocrotaline pulmonary hypertension. J. Appl. Physiol. 65(5), 2326, (1988).
72. Jiang B.H., Tawara S., Abe K., Takaki A., Fukumoto Y., Shimokawa H.: Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J. Cardiovasc. Pharmacol. 49(2), 85, (2007).
73. Batchelor T.J., Sadaba J.R., Ishola A., Pacaud P., Munsch C.M., Beech D.J.: Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. Br. J. Pharmacol. 132(1), 302, (2001).
74. Dhaliwal J.S., Casey D.B., Greco A.J., Badejo A.M., Jr., Gallen T.B., Murthy S.N., Nossaman B.D., Hyman A.L., et al.: Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in LNAME-treated rats. Am. J. Physiol. Lung Cell Mol. Physiol. 293(5), L1306, (2007).
75. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., et al: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389(6654), 990, (1997).
76. Sasaki Y., Suzuki M., Hidaka H.: The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93(2-3), 225, (2002).
77. Hyman A.L., Hao Q., Tower A., Kadowitz P.J., Champion H.C., Gumusel B., Lippton H.: Novel catheterization technique for the in vivo measurement of pulmonary vascular responses in rats. Am. J. Physiol. Heart Circ. Physiol. 274(4), H1218, (1998).
78. Wang J., Weigand L., Foxson J., Shimoda L.A., Sylvester J.T.: Ca2+ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonists. Am. J. Physiol. Lung Cell Mol. Physiol. 293(3), L674, (2007).
79. Nossaman B.D., Kaye A.D., Feng C.J., Kadowitz P.J.: Effects of charybdotoxin on responses to nitrosovasodilators and hypoxia in the rat lung. Am. J. Physiol. 272(4 Pt 1), L787, (1997).
80. Oka M., Homma N., Taraseviciene-Stewart L., Morris K.G., Kraskauskas D., Burns N., Voelkel N.F., McMurtry I.F.: Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ. Res. 100(6), 923, (2007).
81. Guilluy C., Rolli-Derkinderen M., Tharaux P.-L., Melino G., Pacaud P., Loirand G.: Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J. Biol. Chem. 282(5), 2918, (2007).
82. Gao Y., Portugal A.D., Negash S., Zhou W., Longo L.D., Usha R.J.: Role of Rho kinases in PKG-mediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 292(3), L678, (2007).
83. Gao Y., Portugal A.D., Liu J., Negash S., Zhou W., Tian J., Xiang R., Longo L.D., et al.: Preservation of cGMP-induced relaxation of pulmonary veins of fetal lambs exposed to chronic high altitude hypoxia: role of PKG and Rho kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 295(5), L889, (2008).
84. Wang Z., Lanner M.C., Jin N., Swartz D., Li L., Rhoades R.A.: Hypoxia inhibits myosin phosphatase in pulmonary arterial smooth muscle cells: role of Rho-kinase. Am. J. Respir. Cell Mol. Biol. 29(4), 465, (2003).
85. McMurtry I.F., Bauer N.R., Fagan K.A., Nagaoka T., Gebb S.A., Oka M.: Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv. Exp. Med. Biol. 543, 127, (2003).
86. Khan I., Oriowo M.A., Chandrasekhar B., Kadavil E.A.: Attenuated noradrenaline-induced contraction of pulmonary arteries from rats treated with monocrotaline: role of rho kinase. J. Vasc. Res. 42(5), 433, (2005).
87. Nagaoka T., Fagan K.A., Gebb S.A., Morris K.G., Suzuki T., Shimokawa H., McMurtry I.F., Oka M.: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. 171(5), 494, (2005).
88. Fukata Y., Amano M., Kaibuchi K.: Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 22(1), 32, (2001).
89. Abe K., Tawara S., Oi K., Hizume T., Uwatoku T., Fukumoto Y., Kaibuchi K., Shimokawa H.: Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J. Cardiovasc. Pharmacol. 48(6), 280, (2006).
90. Janssen L.J., Lu-Chao H., Netherton S.: Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 280(4), L666, (2001).
91. Martin C., Göggel R., Ressmeyer A.R., Uhlig S.: Pressor responses to platelet-activating factor and thromboxane are mediated by Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 287(1), L250, (2004).
92. Maeda Y., Hirano K., Nishimura J., Sasaki T., Kanaide H.: Rho-kinase inhibitor inhibits both myosin phosphorylation-dependent and -independent enhancement of myofilament Ca2+ sensitivity in the bovine middle cerebral artery. Br. J. Pharmacol. 140(5), 871, (2003).
93. Hizume T., Morikawa K., Takaki A., Abe K., Sunagawa K., Amano M., Kaibuchi K., Kubo C., et al.: Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: a possible link between stress and coronary vasospasm. Circ. Res. 99(7), 767, (2006).
94. Kandabashi T., Shimokawa H., Miyata K., Kunihiro I., Eto Y., Morishige K., Matsumoto Y., Obara K., et al.: Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscler. Thromb. Vasc. Biol. 23(12), 2209, (2003).
95. Shirao S., Kashiwagi S., Sato M., Miwa S., Nakao F., Kurokawa T., Todoroki-Ikeda N., Mogami K., et al.: Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ. Res. 91(2), 112, (2002).
96. Shimokawa H., Morishige K., Miyata K., Kandabashi T., Eto Y., Ikegaki I., Asano T., Kaibuchi K., et al.: Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc. Res. 51(1), 169, (2001).
97. Sato S., Ikegaki I., Asano T., Shimokawa H.: Antiischemic properties of fasudil in experimental models of vasospastic angina. Jpn. J. Pharmacol. 87(1), 34, (2001).
98. Morishige K., Shimokawa H., Eto Y., Kandabashi T., Miyata K., Matsumoto Y., Hoshijima M., Kaibuchi K., et al.: Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler. Thromb. Vasc. Biol. 21(4), 548, (2001).
99. Kandabashi T., Shimokawa H., Miyata K., Kunihiro I., Kawano Y., Fukata Y., Higo T., Egashira K., et al.: Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 101(11), 1319, (2000).
100. Shimokawa H., Seto M., Katsumata N., Amano M., Kozai T., Yamawaki T., Kuwata K., Kandabashi T., et al.: Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 43(4), 1029, (1999).
101. Otsuka T., Ibuki C., Suzuki T., Ishii K., Yoshida H., Kodani E., Kusama Y., Atarashi H., et al.: Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron. Artery Dis. 19(2), 105, (2008).
102. Hiroki J., Shimokawa H., Mukai Y., Ichiki T., Takeshita A.: Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 326(1), 154, (2005).
103. Inokuchi K., Ito A., Fukumoto Y., Matoba T., Shiose A., Nishida T., Masuda M., Morita S., Shimokawa H.: Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J. Cardiovasc. Pharmacol. 3, 275, (2004).
104. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., Kubota T., Ichiki T., et al.: Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J. Mol. Cell. Cardiol. 37(2), 537, (2004).
105. Hiroki J., Fukumoto Y., Shimokawa H., Hirooka Y., Takeshita A.: [Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report]. J. Cardiol. 4, 161, (2004).
106. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., Takeshita A.: Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 41(1), 15, (2003).
107. Masumoto A., Mohri M., Shimokawa H., Urakami L., Usui M., Takeshita A.: Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105(13), 1545, (2002).
108. Fukumoto Y., Mohri M., Inokuchi K., Ito A., Hirakawa Y., Masumoto A., Hirooka Y., Takeshita A., et al.: Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J. Cardiovasc. Pharmacol. 49(3), 117, (2007).
109. Satoh S.-I., Ikegaki I., Toshima Y., Watanabe A., Asano T., Shimokawa H.: Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. Life Sci. 72(1), 103, (2002).
110. Halcox J.P.J., Schenke W.H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M.A., Nour K.R.A., Quyyumi A.A.: Prognostic value of coronary vascular endothelial dysfunction. Circulation 106(6), 653, (2002).
111. Utsunomiya T., Satoh S., Ikegaki I., Toshima Y., Asano T., Shimokawa H.: Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br. J. Pharmacol. 134(8), 1724, (2001).
112. Yamamoto Y., Ikegaki I., Sasaki Y., Uchida T.: The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit. J. Cardiovasc. Pharmacol. 35(2), 203, (2000).
113. Otsuka T., Ibuki C., Suzuki T., Ishii K., Kodani E., Atarashi H., Kishida H., Takano T.: Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ. J. 70(4), 402, (2006).
114. Shimokawa H., Hiramori K., Iinuma H., Hosoda S., Kishida H., Osada H., Katagiri T., Yamauchi K., et al.: Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J. Cardiovasc. Pharmacol. 40(5), 751, (2002).
115. Witzenrath M., Ahrens B., Schmeck B., Kube S.M., Hippenstiel S., Rosseau S., Hamelmann E., Suttorp N., Schütte H.: Rho-kinase and contractile apparatus proteins in murine airway hyperresponsiveness. Exp. Toxicol. Pathol. 60(1), 9, (2008).
116. Taki F., Kume H., Kobayashi T., Ohta H., Aratake H., Shimokata K.: Effects of Rho-kinase inactivation on eosinophilia and hyper-reactivity in murine airways by allergen challenges. Clin. Exp. Allergy 37(4), 599, (2007).
117. Matsumoto H., Moir L.M., Oliver B.G., Burgess J.K., Roth M., Black J.L., McParland B.E.: Comparison of gel contraction mediated by asthmatic and non-asthmatic airway smooth muscle cells. Thorax 62(10), 848, (2007).
118. Kojima K., Kume H., Ito S., Oguma T., Shiraki A., Kondo M., Ito Y., Shimokata K.: Direct effects of hydrogen peroxide on airway smooth muscle tone: roles of Ca2+ influx and Rho-kinase. Eur. J. Pharmacol. 556(1-3), 151, (2007).
119. Schaafsma D., Bos I.S.T., Zuidhof A.B., Zaagsma J., Meurs H.: Inhalation of the Rho-kinase inhibitor Y-27632 reverses allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction. Respir. Res. 7, 121, (2006).
120. Liu C., Tazzeo T., Janssen L.J.: Isoprostane-induced airway hyperresponsiveness is dependent on internal Ca2+ handling and Rho/ROCK signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 291(6), L1177, (2006).
121. Yamada A., Hirose K., Hashimoto A., Iino M.: Real-time imaging of myosin II regulatory light-chain phosphorylation using a new protein biosensor. Biochem. J. 385(Pt 2), 589, (2005).
122. Liu C., Zuo J., Pertens E., Helli P.B., Janssen L.J.: Regulation of Rho/ROCK signaling in airway smooth muscle by membrane potential and [Ca2+]i. Am. J. Physiol. Lung Cell Mol. Physiol. 289(4), L574, (2005).
123. Henry P.J., Mann T.S., Goldie R.G.: A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm. Pharmacol. Ther. 18(1), 67, (2005).
124. Schaafsma D., Gosens R., Bos I.S.T., Meurs H., Zaagsma J., Nelemans S.A.: Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction. Br. J. Pharmacol. 143(4), 477, (2004).
125. McElhinney B., Poynter M.E., Shrivastava P., Hazen S.L., Janssen-Heininger Y.M.W.: Eosinophil peroxidase catalyzes JNK-mediated membrane blebbing in a Rho kinase-dependent manner. J. Leukoc. Biol. 74(5), 897, (2003).
126. Tokuyama K., Nishimura H., Iizuka K., Kato M., Arakawa H., Saga R., Mochizuki H., Morikawa A.: Effects of Y-27632, a Rho/Rho kinase inhibitor, on leukotriene D(4)- and histamine-induced airflow obstruction and airway microvascular leakage in guinea pigs in vivo. Pharmacology 64(4), 189, (2002).
127. Nakahara T., Moriuchi H., Yunoki M., Sakamato K., Ishii K.: Y-27632 potentiates relaxant effects of beta 2-adrenoceptor agonists in bovine tracheal smooth muscle. Eur. J. Pharmacol. 389(1), 103, (2000).
128. Kobayashi M., Kume H., Oguma T., Makino Y., Ito Y., Shimokata K.: Mast cell tryptase causes homologous desensitization of beta-adrenoceptors by Ca2+ sensitization in tracheal smooth muscle. Clin. Exp. Allergy 38(1), 135, (2008).
129. Shin Y., Yoon S.-H., Choe E.-Y., Cho S.-H., Woo C.-H., Rho J.-Y., Kim J.-H.: PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. Exp. Mol. Med. 39(1), 97, (2007).
130. Kume H., Takeda N., Oguma T., Ito S., Kondo M., Ito Y., Shimokata K.: Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation. J. Pharmacol. Exp. Ther. 320(2), 766, (2007).
131. Urata Y., Nishimura Y., Hirase T., Yokoyama M.: Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. Kobe J. Med. Sci. 51(1-2), 17, (2005).
132. Szabó H., Novák Z., Bauer H., Szatmári E., Farkas A., Wejksza K., Orbók A., Wilhelm I., et al.: Regulation of proteolytic activity induced by inflammatory stimuli in lung epithelial cells. Cell Mol. Biol. (Noisy-le-grand) 51 Suppl, OL729, (2005).
133. Janssen L.J., Tazzeo T., Zuo J., Pertens E., Keshavjee S.: KCl evokes contraction of airway smooth muscle via activation of RhoA and Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 287(4), L852, (2004).
134. Chiba Y., Misawa M.: The role of RhoA-mediated Ca2+ sensitization of bronchial smooth muscle contraction in airway hyperresponsiveness. J. Smooth Muscle Res. 40(4-5), 155, (2004).
135. Tazzeo T., Miller J., Janssen L.J.: Vasoconstrictor responses, and underlying mechanisms, to isoprostanes in human and porcine bronchial arterial smooth muscle. Br. J. Pharmacol. 140(4), 759, (2003).
136. Rosenfeldt H.M., Amrani Y., Watterson K.R., Murthy K.S., Panettieri R.A., Spiegel S.: Sphingosine-1-phosphate stimulates contraction of human airway smooth muscle cells. FASEB J. 17(13), 1789, (2003).
137. Hunter I., Cobban H.J., Vandenabeele P., MacEwan D.J., Nixon G.F.: Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: role in the Ca2+ sensitization of myosin light chain20 phosphorylation. Mol. Pharmacol. 63(3), 714, (2003).
138. Hashimoto K., Peebles R.S., Sheller J.R., Jarzecka K., Furlong J., Mitchell D.B., Hartert T.V., Graham B.S.: Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor. Thorax 57(6), 524, (2002).
139. Setoguchi H., Nishimura J., Hirano K., Takahashi S., Kanaide H.: Leukotriene C(4) enhances the contraction of porcine tracheal smooth muscle through the activation of Y-27632, a rho kinase inhibitor, sensitive pathway. Br. J. Pharmacol. 132(1), 111, (2001).
140. Janssen L.J., Premji M., Netherton S., Coruzzi J., Lu-Chao H., Cox P.G.: Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. Br. J. Pharmacol. 132(1), 127, (2001).
141. Ishizuka T., Okajima F., Ishiwara M., Iizuka K., Ichimonji I., Kawata T., Tsukagoshi H., Dobashi K., et al.: Sensitized mast cells migrate toward the antigen: a response regulated by p38 mitogen-activated protein kinase and Rho-associated coiled-coil-forming protein kinase. J. Immunol. 167(4), 2298, (2001).
142. Ohnaka K., Shimoda S., Nawata H., Shimokawa H., Kaibuchi K., Iwamoto Y., Takayanagi R.: Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287(2), 337, (2001).
143. Yoneda H., Shirao S., Kurokawa T., Fujisawa H., Kato S., Suzuki M.: Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage? Acta Neurol. Scand. 118(1), 54, (2008).
144. Pyne-Geithman G.J., Nair S.G., Caudell D.N., Clark J.F.: PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF. Front. Biosci. 13, 1526, (2008).
145. Liu P.-Y., Liao J.K.: A method for measuring rho kinase activity in tissues and cells. Methods Enzymol. 439, 181, (2008).
146. Watanabe Y., Faraci F.M., Heistad D.D.: Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage. Am. J. Physiol. Heart Circ. Physiol. 288(6), H2653, (2005).
147. Obara K., Nishizawa S., Koide M., Nozawa K., Mitate A., Ishikawa T., Nakayama K.: Interactive role of protein kinase C-delta with rho-kinase in the development of cerebral vasospasm in a canine two-hemorrhage model. J. Vasc. Res. 42(1), 67, (2005).
148. Tani E., Matsumoto T.: Continuous elevation of intracellular Ca2+ is essential for the development of cerebral vasospasm. Curr. Vasc. Pharmacol. 2(1), 13, (2004).
149. Lan C., Das D., Wloskowicz A., Vollrath B.: Endothelin-1 modulates hemoglobin-mediated signaling in cerebrovascular smooth muscle via RhoA/Rho kinase and protein kinase C. Am. J. Physiol. Heart Circ. Physiol. 286(1), H165, (2004).
150. Wickman G., Lan C., Vollrath B.: Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm. Circ. Res. 92(7), 809, (2003).
151. Breitenlechner C., Gassel M., Hidaka H., Kinzel V., Huber R., Engh R.A., Bossemeyer D.: Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11(12), 1595, (2003).
152. Tosaka M., Okajima F., Hashiba Y., Saito N., Nagano T., Watanabe T., Kimura T., Sasaki T.: Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 32(12), 2913, (2001).
153. Sato M., Tani E., Fujikawa H., Kaibuchi K.: Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ. Res. 87(3), 195, (2000).
154. Miyagi Y., Carpenter R.C., Meguro T., Parent A.D., Zhang J.H.: Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J. Neurosurg. 93(3), 471, (2000).
155. Iwasaki H., Okamoto R., Kato S., Konishi K., Mizutani H., Yamada N., Isaka N., Nakano T., et al.: High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 196(1), 22, (2008).
156. Harrison B.C., Kim M.-S., van Rooij E., Plato C.F., Papst P.J., Vega R.B., McAnally J.A., Richardson J.A., et al.: Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell. Biol. 26(10), 3875, (2006).
157. Rikitake Y., Oyama N., Wang C.-Y.C., Noma K., Satoh M., Kim H.-H., Liao J.K.: Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 112(19), 2959, (2005).
158. Qvigstad E., Sjaastad I., Brattelid T., Nunn C., Swift F., Birkeland J.A.K., Krobert K.A., Andersen G.Ø., et al.: Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart. Circ. Res. 97(3), 268, (2005).
159. Demiryürek S., Kara A.F., Celik A., Babül A., Tarakçioglu M., Demiryürek A.T.: Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Eur. J. Pharmacol. 527(1-3), 129, (2005).
160. Sanada S., Asanuma H., Tsukamoto O., Minamino T., Node K., Takashima S., Fukushima T., Ogai A., et al.: Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 110(1), 51, (2004).
161. Hamid S.A., Bower H.S., Baxter G.F.: Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am. J. Physiol. Heart Circ. Physiol. 292(6), H2598, (2007).
162. Steffel J., Akhmedov A., Greutert H., Lüscher T.F., Tanner F.C.: Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 112(3), 341, (2005).
163. Jin H.G., Yamashita H., Nagano Y., Fukuba H., Hiji M., Ohtsuki T., Takahashi T., Kohriyama T., Kaibuchi K., et al.: Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci. Lett. 408(1), 62, (2006).
164. Vicari R.M., Chaitman B., Keefe D., Smith W.B., Chrysant S.G., Tonkon M.J., Bittar N., Weiss R.J., et al: Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 46(10), 1803, (2005).
165. Kishore R., Qin G., Luedemann C., Bord E., Hanley A., Silver M., Gavin M., Yoon Y.-S., et al.: The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J. Clin. Invest. 115(7), 1785, (2005).
166. Wolfrum S., Dendorfer A., Rikitake Y., Stalker T.J., Gong Y., Scalia R., Dominiak P., Liao J.K.: Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 24(10), 1842, (2004).
167. Assmus B., Urbich C., Aicher A., Hofmann W.K., Haendeler J., Rössig L., Spyridopoulos I., Zeiher A.M., et al.: HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92(9), 1049, (2003).
168. Renieri G., Choritz L., Rosenthal R., Meissner S., Pfeiffer N., Thieme H.: Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork. Graefes Arch. Clin. Exp. Ophthalmol. 246(8), 1107, (2008).
169. Lu Z., Overby D.R., Scott P.A., Freddo T.F., Gong H.: The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp. Eye Res. 86(2), 271, (2008).
170. Hasegawa Y., Nishimura J., Niiro N., Hirano K., Ishibashi T., Kanaide H.: Prostaglandin F2alpha, but not latanoprost, increases the Ca2+ sensitivity of the pig iris sphincter muscle. Invest. Ophthalmol. Vis. Sci. 47(11), 4865, (2006).
171. Waki M., Yoshida Y., Oka T., Azuma M.: Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr. Eye Res. 22(6), 470, (2001).
172. Meyer-ter-Vehn T., Sieprath S., Katzenberger B., Gebhardt S., Grehn F., Schlunck G.: Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci. 47(11), 4895, (2006).
173. Rosenthal R., Choritz L., Schlott S., Bechrakis N.E., Jaroszewski J., Wiederholt M., Thieme H.: Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp. Eye Res. 80(6), 837, (2005).
174. Rao P.V., Deng P., Maddala R., Epstein D.L., Li C.-Y., Shimokawa H.: Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow. Mol. Vis. 11, 288, (2005).
175. Rao P.V., Deng P.F., Kumar J., Epstein D.L.: Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest. Ophthalmol. Vis. Sci. 42(5), 1029, (2001).
176. Honjo M., Tanihara H., Inatani M., Kido N., Sawamura T., Yue B.Y., Narumiya S., Honda Y.: Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest. Ophthalmol. Vis. Sci. 42(1), 137, (2001).
177. Lin W.-Y., Mannikarottu A., Chichester P., Guven A., Johnson A., Neuman P., Juan Y.-S., Schuler C., et al.: Changes in the smooth muscle of the corpora cavernosum related to reversal of partial bladder outlet obstruction in rabbits. J. Androl. 29(2), 164, (2008).
178. Kolavennu V., Zeng L., Peng H., Wang Y., Danesh F.R.: Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57(3), 714, (2008).
179. Wingard C., Fulton D., Husain S.: Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J. Sex. Med. 4(2), 348, (2007).
180. Vignozzi L., Morelli A., Filippi S., Ambrosini S., Mancina R., Luconi M., Mungai S., Vannelli G.B., et al.: Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J. Sex. Med. 4(3), 620, (2007).
181. Park K., Kim S.W., Rhu K.S., Paick J.-S.: Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J. Sex. Med. 3(6), 996, (2006).
182. Teixeira C.E., Ying Z., Webb R.C.: Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl] homopiperazine (H-1152) in the rat penis. J. Pharmacol Exp. Ther. 315(1), 155, (2005).
183. Dai Y., Chitaley K., Webb R.C., Lewis R.W., Mills T.M.: Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int. J. Impot. Res. 16(3), 294, (2004).
184. Takahashi R., Nishimura J., Hirano K., Naito S., Kanaide H.: Modulation of Ca2+ sensitivity regulates contractility of rabbit corpus cavernosum smooth muscle. J. Urol. 169(6), 2412, (2003).
185. Buyukafsar K., Levent A., Ark M.: Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br. J. Pharmacol. 140(4), 743, (2003).
186. Chitaley K., Webb R.C., Dorrance A.M., Mills T.M.: Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats. Int. J. Impot. Res. 13 Suppl 5, S16, (2001).
187. Gur S., Kadowitz P.J., Trost L., Hellstrom W.J.: Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum. J. Urol. 178(4 Pt 1), 1543, (2007).
188. Musicki B., Burnett A.L.: eNOS function and dysfunction in the penis. Exp. Biol. Med. (Maywood) 231(2), 154, (2006).
189. Demir O., Murat N., Aslan G., Gidener S., Esen A.A.: Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J. Urol. 175(6), 2345, (2006).
190. Wang H., Eto M., Steers W.D., Somlyo A.P., Somlyo A.V.: RhoA-mediated Ca2+ sensitization in erectile function. J. Biol. Chem. 277(34), 30614, (2002).
191. Williams J., Bogwu J., Oyekan A.: The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice. J. Hypertens. 24(7), 1429, (2006).
192. Hennenberg M., Biecker E., Trebicka J., Jochem K., Zhou Q., Schmidt M., Jakobs K.H., Sauerbruch T., et al.: Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 130(3), 838, (2006).
193. Chapados R., Abe K., Ihida-Stansbury K., McKean D., Gates A.T., Kern M., Merklinger S., Elliott J., et al.: ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. Circ. Res. 99(8), 837, (2006).
194. Rajasekaran M., Wilkes N., Kuntz S., E Albo M.: Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. Neurourol. Urodyn. 24(3), 295, (2005).
195. Sawada N., Itoh H., Ueyama K., Yamashita J., Doi K., Chun T.H., Inoue M., Masatsugu K., Saito T., et al.: Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101(17), 2030, (2000).
196. Doe C., Bentley R., Behm D.J., Lafferty R., Stavenger R., Jung D., Bamford M., Panchal T., et al.: Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities. J. Pharmacol. Exp. Ther. 320(1), 89, (2007).
197. Seasholtz T.M., Wessel J., Rao F., Rana B.K., Khandrika S., Kennedy B.P., Lillie E.O., Ziegler M.G., et al.: Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension 47(5), 937, (2006).
198. Archer S.L., Michelakis E.D., Thébaud B., Bonnet S., Moudgil R., Wu X.-C., Weir E.K.: A central role for oxygen-sensitive K+ channels and mitochondria in the specialized oxygen-sensing system. Novartis Found. Symp. 272, 157, (2006).
199. Masumoto A., Hirooka Y., Shimokawa H., Hironaga K., Setoguchi S., Takeshita A.: Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38(6), 1307, (2001).
200. Iso Y., Suzuki H., Sato T., Shoji M., Shimizu N., Shibata M., Koba S., Geshi E., et al.: Rho-kinase inhibitor suppressed restenosis in porcine coronary balloon angioplasty. Int. J. Cardiol. 106(1), 103, (2006).
201. Pearce J.D., Li J., Edwards M.S., English W.P., Geary R.L.: Differential effects of Rho-kinase inhibition on artery wall mass and remodeling. J. Vasc. Surg. 39(1), 223, (2004).
202. Matsumoto Y., Uwatoku T., Oi K., Abe K., Hattori T., Morishige K., Eto Y., Fukumoto Y., et al.: Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler. Thromb. Vasc. Biol. 24(1), 181, (2004).
203. Yamamoto T., Takeda K., Harada S., Nakata T., Azuma A., Sasaki S., Nakagawa M.: HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway. Atherosclerosis 166(2), 213, (2003).
204. Chaulet H., Desgranges C., Renault M.A., Dupuch F., Ezan G., Peiretti F., Loirand G., Pacaud P., et al.: Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ. Res. 89(9), 772, (2001).
205. Eto Y., Shimokawa H., Hiroki J., Morishige K., Kandabashi T., Matsumoto Y., Amano M., Hoshijima M., et al.: Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am. J. Physiol. Heart Circ. Physiol. 278(6), H1744, (2000).
206. Seasholtz T.M., Majumdar M., Kaplan D.D., Brown J.H.: Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ. Res. 84(10), 1186, (1999).
207. Guérin P., Sauzeau V., Rolli-Derkinderen M., Al H.O., Scalbert E., Crochet D., Pacaud P., Loirand G.: Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J. Vasc. Res. 42(1), 21, (2005).
208. Taoufiq Z., Gay F., Balvanyos J., Ciceron L., Tefit M., Lechat P., Mazier D.: Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. J. Infect. Dis. 197(7), 1062, (2008).
209. Petratos S., Li Q.-X., George A.J., Hou X., Kerr M.L., Unabia S.E., Hatzinisiriou I., Maksel D., et al.: The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain 131(Pt 1), 90, (2008).
210. Wang S., Lee S.-R., Guo S.-Z., Kim W.J., Montaner J., Wang X., Lo E.H.: Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 37(7), 1910, (2006).
211. Tanaka H., Katoh H., Negishi M.: Pragmin, a novel effector of Rnd2 GTPase, stimulates RhoA activity. J. Biol. Chem. 281(15), 10355, (2006).
212. Baruffini E., Lodi T., Dallabona C., Puglisi A., Zeviani M., Ferrero I.: Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive external ophthalmoplegia in humans. Hum. Mol. Genet. 15(19), 2846, (2006).
213. Rikitake Y., Kim H.-H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., Liao J.K.: Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36(10), 2251, (2005).
214. Jalil J., Lavandero S., Chiong M., Ocaranza M.P.: [Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling]. Rev. Esp. Cardiol. 58(8), 951, (2005).
215. Annabi B., Bouzeghrane M., Moumdjian R., Moghrabi A., Béliveau R.: Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg. J. Neurochem. 94(4), 906, (2005).
216. Salomone S., Yoshimura S.-I., Reuter U., Foley M., Thomas S.S., Moskowitz M.A., Waeber C.: S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur. J. Pharmacol. 469(1-3), 125, (2003).
217. Satoh S., Kobayashi T., Hitomi A., Ikegaki I., Suzuki Y., Shibuya M., Yoshida J., Asano T.: Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn. J. Pharmacol. 80(1), 41, (1999).
218. Wang L., Ellis M.J., Fields T.A., Howell D.N., Spurney R.F.: Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis. Kidney Blood Press. Res. 31(2), 111, (2008).
219. Sugano N., Wakino S., Kanda T., Tatematsu S., Homma K., Yoshioka K., Hasegawa K., Hara Y., et al.: T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 73(7), 826, (2008).
220. Maruta T., Yanagita T., Matsuo K., Uezono Y., Satoh S., Nemoto T., Yoshikawa N., Kobayashi H., et al.: Lysophosphatidic acid-LPA1 receptor-Rho-Rho kinase-induced up-regulation of Nav1.7 sodium channel mRNA and protein in adrenal chromaffin cells: enhancement of 22Na+ influx, 45Ca2+ influx and catecholamine secretion. J. Neurochem. 105(2), 401, (2008).
221. Yousif M.H.M.: Role of protein kinases in mediating diabetes-induced augmented vasoconstriction to endothelin-1 in the renal arteries of STZ-diabetic rats. Cell Biochem. Funct. 24(5), 397, (2006).
222. Roos M.H., van Rrodijnen W.F., van Lambalgen A.A., ter Wee P.M., Tangelder G.J.: Renal microvascular constriction to membrane depolarization and other stimuli: pivotal role for rho-kinase. Pflugers Arch. 452(4), 471, (2006).
223. Banes-Berceli A.K., Shaw S., Ma G., Brands M., Eaton D.C., Stern D.M., Fulton D., Caldwell R.W., et al.: Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am. J. Physiol. Renal Physiol. 291(1), F116, (2006).
224. Mita S.-I., Kobayashi N., Yoshida K., Nakano S., Matsuoka H.: Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J. Hypertens. 23(1), 87, (2005).
225. Prahalad P., Calvo I., Waechter H., Matthews J.B., Zuk A., Matlin K.S.: Regulation of MDCK cell-substratum adhesion by RhoA and myosin light chain kinase after ATP depletion. Am. J. Physiol. Cell Physiol. 286(3), C693, (2004).
226. Nakamura A., Hayashi K., Ozawa Y., Fujiwara K., Okubo K., Kanda T., Wakino S., Saruta T.: Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. J. Vasc. Res. 40(3), 244, (2003).
227. Bing W., Chang S., Hypolite J.A., DiSanto M.E., Zderic S.A., Rolf L., Wein A.J., Chacko S.: Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am. J. Physiol. Renal Physiol. 285(5), F990, (2003).
228. Maeda A., Amano M., Fukata Y., Kaibuchi K.: Translocation of Na(+),K(+)-ATPase is induced by Rho small GTPase in renal epithelial cells. Biochem. Biophys. Res. Commun. 297(5), 1231, (2002).
229. Tamma G., Klussmann E., Maric K., Aktories K., Svelto M., Rosenthal W., Valenti G.: Rho inhibits cAMP-induced translocation of aquaporin-2 into the apical membrane of renal cells. Am. J. Physiol. Renal Physiol. 281(6), F1092, (2001).
230. Klussmann E., Tamma G., Lorenz D., Wiesner B., Maric K., Hofmann F., Aktories K., Valenti G., et al.: An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J. Biol. Chem. 276(23), 20451, (2001).
231. Kanda S., Kanetake H., Miyata Y.: Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility. Mol. Cell Biochem. 309(1-2), 69, (2008).
232. Zhang J.J., Kelm R.J., Biswas P., Kashgarian M., Madri J.A.: PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells. J. Cell Physiol. 210(2), 527, (2007).
233. Tesfamariam B.: The effects of HMG-CoA reductase inhibitors on endothelial function. Am. J. Cardiovasc. Drugs 6(2), 115, (2006).
234. Tapia P.C.: RhoA, Rho kinase, JAK2, and STAT3 may be the intracellular determinants of longevity implicated in the progeric influence of obesity: Insulin, IGF-1, and leptin may all conspire to promote stem cell exhaustion. Med. Hypotheses 66(3), 570, (2006).
235. Lindberg C., Klintberg L., Oldfors A.: Raised troponin T in inclusion body myositis is common and serum levels are persistent over time. Neuromuscul. Disord. 16(8), 495, (2006).
236. Horiguchi A., Sumitomo M., Asakuma J., Asano T., Zheng R., Asano T., Nanus D.M., Hayakawa M.: Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J. Urol. 176(4 Pt 1), 1636, (2006).
237. Graness A., Cicha I., Goppelt-Struebe M.: Contribution of Src-FAK signaling to the induction of connective tissue growth factor in renal fibroblasts. Kidney Int. 69(8), 1341, (2006).
238. Crean J.K., Furlong F., Mitchell D., McArdle E., Godson C., Martin F.: Connective tissue growth factor/CCN2 stimulates actin disassembly through Akt/protein kinase B-mediated phosphorylation and cytoplasmic translocation of p27(Kip-1). FASEB J. 20(10), 1712, (2006).
239. Turcotte S., Desrosiers R.R., Brand G., Béliveau R.: von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation. Int. J. Cancer. 112(5), 777, (2004).
240. Hahn A., Heusinger-Ribeiro J., Lanz T., Zenkel S., Goppelt-Struebe M.: Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J. Biol. Chem. 275(48), 37429, (2000).
241. Yu L., Quinn D.A., Garg H.G., Hales C.A.: Deficiency of NHE1 Gene Prevents Hypoxia-Induced Pulmonary Hypertension and Vascular Remodeling. Am. J. Respir. Crit. Care Med. 177(11), 1276, (2008).
242. Snetkov V.A., Thomas G.D., Teague B., Leach R.M., Shaifta Y., Knock G.A., Aaronson P.I., Ward J.P.T.: Low concentrations of sphingosylphosphorylcholine enhance pulmonary artery vasoreactivity: the role of protein kinase C delta and Ca2+ entry. Hypertension 51(2), 239, (2008).
243. Xing X.-Q., Gan Y., Wu S.-J., Chen P., Zhou R., Xiang X.-D.: Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. Med. Hypotheses. 68(5), 1108, (2007).
244. Girgis R.E., Mozammel S., Champion H.C., Li D., Peng X., Shimoda L., Tuder R.M., Johns R.A, et al.: Regression of Chronic Hypoxic Pulmonary Hypertension by Simvastatin. Am. J. Physiol. Lung Cell Mol. Physiol. 292(5), L1105, (2007).
245. Crossno J.T., Garat C.V., Reusch J.E.B., Morris K.G., Dempsey E.C., McMurtry I.F., Stenmark K.R., Klemm D.J.: Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. 292(4), L885, (2007).
246. Barman S.A.: Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am. J. Physiol. Lung Cell Mol. Physiol. 293(2), L472, (2007).
247. Yi S.L., Kantores C., Belcastro R., Cabacungan J., Tanswell A.K., Jankov R.P.: 8-Isoprostane-induced endothelin-1 production by infant rat pulmonary artery smooth muscle cells is mediated by Rho-kinase. Free Radic. Biol. Med. 41(6), 942, (2006).
248. Weir E.K., Olschewski A.: Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. Cardiovasc. Res. 71(4), 630, (2006).
249. Guilluy C., Sauzeau V., Rolli-Derkinderen M., Guérin P., Sagan C., Pacaud P., Loirand G.: Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br. J. Pharmacol. 146(7), 1010, (2005).
250. Cogolludo A., Moreno L., Lodi F., Tamargo J., Perez-Vizcaino F.: Postnatal maturational shift from PKCzeta and voltage-gated K+ channels to RhoA/Rho kinase in pulmonary vasoconstriction. Cardiovasc. Res. 66(1), 84, (2005).
251. Liu Y., Suzuki Y.J., Day R.M., Fanburg B.L.: Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res. 95(6), 579, (2004).
252. Belik J., Jankov R.P., Pan J., Tanswell A.K.: Peroxynitrite inhibits relaxation and induces pulmonary artery muscle contraction in the newborn rat. Free Radic. Biol. Med. 37(9), 1384, (2004).
253. Sauzeau V., Rolli-Derkinderen M., Lehoux S., Loirand G., Pacaud P.: Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ. Res. 93(7), 630, (2003).
254. Cogolludo A., Moreno L., Bosca L., Tamargo J., Perez-Vizcaino F.: Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. Circ. Res. 93(7), 656, (2003).
255. Satoh S.-I., Toshima Y., Hitomi A., Ikegaki I., Seto M., Asano T.: Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res. 1193, 102, (2008).
256. Shin H.K., Salomone S., Potts E.M., Lee S.-W., Millican E., Noma K., Huang P.L., Boas D.A., et al.: Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J. Cereb. Blood Flow Metab. 27(5), 998, (2007).
257. Nishikimi T., Koshikawa S., Ishikawa Y., Akimoto K., Inaba C., Ishimura K., Ono H., Matsuoka H.: Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J. Hypertens. 25(5), 1053, (2007).
258. Zhang Z., Ottens A.K., Larner S.F., Kobeissy F.H., Williams M.L., Hayes R.L., Wang K.K.W.: Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells. Cell Mol. Biol. Lett. 11(1), 12, (2006).
259. Shin H.K., Salomone S., Potts E.M., Lee S.-W., Millican E., Noma K., Huang P.L., Boas D.A., et al.: Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J. Cereb. Blood Flow Metab. 27(5), 998, (2007).
260. Scherer E.Q., Lidington D., Oestreicher E., Arnold W., Pohl U., Bolz S.-S.: Sphingosine-1-phosphate modulates spiral modiolar artery tone: A potential role in vascular-based inner ear pathologies? Cardiovasc. Res. 70(1), 79, (2006).
261. Savoia C., Ebrahimian T., He Y., Gratton J.-P., Schiffrin E.L., Touyz R.M.: Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J. Hypertens. 24(12), 2417, (2006).
262. Savoia C., Tabet F., Yao G., Schiffrin E.L., Touyz R.M.: Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J. Hypertens. 23(5), 1037, (2005).
263. Didion S.P., Lynch C.M., Baumbach G.L., Faraci F.M.: Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes. Stroke 36(2), 342, (2005).
264. Moriki N., Ito M., Seko T., Kureishi Y., Okamoto R., Nakakuki T., Kongo M., Isaka N., et al.: RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens. Res. 27(4), 263, (2004).
265. Seko T., Ito M., Kureishi Y., Okamoto R., Moriki N., Onishi K., Isaka N., Hartshorne D.J., et al.: Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92(4), 411, (2003).
266. Scherer E.Q., Herzog M., Wangemann P.: Endothelin-1-induced vasospasms of spiral modiolar artery are mediated by rho-kinase-induced Ca(2+) sensitization of contractile apparatus and reversed by calcitonin gene-related Peptide. Stroke 33(12), 2965, (2002).
267. Satoh S., Utsunomiya T., Tsurui K., Kobayashi T., Ikegaki I., Sasaki Y., Asano T.: Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 69(12), 1441, (2001).
268. Toshima Y., Satoh S., Ikegaki I., Asano T.: A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 31(9), 2245, (2000).
269. Muñoz-García B., Martín-Ventura J.L., Martínez E., Sánchez S., Hernández G., Ortega L., Ortiz A., Egido J., et al.: Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37(8), 2044, (2006).
270. Chrissobolis S., Sobey C.G.: Recent evidence for an involvement of rho-kinase in cerebral vascular disease. Stroke 37(8), 2174, (2006).
271. Rikitake Y., Liao J.K.: Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111(24), 3261, (2005).
272. Sawada K., Morishige K.-I., Mabuchi S., Ogata S., Kawase C., Sakata M., Kimura T.: In vitro and in vivo assays to analyze the contribution of rho kinase in angiogenesis. Methods Enzymol. 439, 395, (2008).
273. Alvarez B., Stroeken P.J.M., Edel M.J., Roos E.: Integrin Cytoplasmic domain-Associated Protein-1 (ICAP-1) promotes migration of myoblasts and affects focal adhesions. J. Cell Physiol. 214(2), 474, (2008).
274. Schmidt A., Durgan J., Magalhaes A., Hall A.: Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from cytokinesis. EMBO J. 26(6), 1624, (2007).
275. Ogawa T., Tashiro H., Miyata Y., Ushitora Y., Fudaba Y., Kobayashi T., Arihiro K., Okajima M., et al.: Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am. J. Transplant. 7(2), 347, (2007).
276. Choma D.P., Milano V., Pumiglia K.M., DiPersio C.M.: Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J. Invest. Dermatol. 127(1), 31, (2007).
277. Verdier V., Guang Chao C., Settleman J.: Rho-kinase regulates tissue morphogenesis via non-muscle myosin and LIM-kinase during Drosophila development. BMC Dev. Biol. 6, 38, (2006).
278. Shim H., Lee H., Jeoung D.: Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK). Biotechnol. Lett. 28(24), 2057, (2006).
279. Hwang S.-Y., Jung J.-W., Jeong J.-S., Kim Y.-J., Oh E.-S., Kim T.-H., Kim J.-Y., Cho K.-H., Han I.-O.: Dominant-negative Rac increases both inherent and ionizing radiation-induced cell migration in C6 rat glioma cells. Int. J. Cancer 118(8), 2056, (2006).
280. Carothers A.M., Javid S.H., Moran A.E., Hunt D.H., Redston M., Bertagnolli M.M.: Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp. Cell Res. 312(4), 387, (2006).
281. Helfman D.M., Pawlak G.: Myosin light chain kinase and acto-myosin contractility modulate activation of the ERK cascade downstream of oncogenic Ras. J. Cell Biochem. 95(5), 1069, (2005).
282. Liu H., Shaw C.-K., Reineke E.L., Liu Y., Kao H.-Y.: Retinoid X receptor alpha (RXRalpha) helix 12 plays an inhibitory role in the recruitment of the p160 co-activators by unliganded RXRalpha/retinoic acid receptor alpha heterodimers. J. Biol. Chem. 279(43), 45208, (2004).
283. Sordella R., Jiang W., Chen G.-C., Curto M., Settleman J.: Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 113(2), 147, (2003).
284. Fournès B., Farrah J., Olson M., Lamarche-Vane N., Beauchemin N.: Distinct Rho GTPase activities regulate epithelial cell localization of the adhesion molecule CEACAM1: involvement of the CEACAM1 transmembrane domain. Mol. Cell Biol. 23(20), 7291, (2003).
285. Tran Q.C., Gautreau A., Arpin M., Treisman R.: Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J. 19(17), 4565, (2000).
286. Kranenburg O., Poland M., van Horck F.P., Drechsel D., Hall A., Moolenaar W.H.: Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction. Mol. Biol. Cell 10(6), 1851, (1999).
287. Goto H., Kosako H., Tanabe K., Yanagida M., Sakurai M., Amano M., Kaibuchi K., Inagaki M.: Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J. Biol. Chem. 273(19), 11728, (1998).
288. Vincent S., Settleman J.: The PRK2 kinase is a potential effector target of both Rho and Rac GTPases and regulates actin cytoskeletal organization. Mol. Cell Biol. 17(4), 2247, (1997).
289. Pinner S., Sahai E.: PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat. Cell Biol. 10(2), 127, (2008).
290. Nie D., Guo Y., Yang D., Tang Y., Chen Y., Wang M.-T., Zacharek A., Qiao Y., et al.: Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res. 68(1), 115, (2008).
291. Kim M.H., Park J.S., Chang H.J., Baek M.K., Kim H.R., Shin B.A., Ahn B.W., Jung Y.D.: Lysophosphatidic acid promotes cell invasion by upregulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. J. Cell Biochem. 104(3), 1102, (2008).
292. Scott G.A., Arioka M., Jacobs S.E.: Lysophosphatidylcholine mediates melanocyte dendricity through PKCzeta activation. J. Invest. Dermatol. 127(3), 668, (2007).
293. Rho J.K., Choi Y.J., Ryoo B.-Y., Na I.I.I., Yang S.H., Kim C.H., Lee J.C.: p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 67(3), 1163, (2007).
294. Pertia A., Nikoleishvili D., Trsintsadze O., Gogokhia N., Managadze L., Chkhotua A.: Loss of p27((Kip1) )CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int. Urol. Nephrol. 39(2), 381, (2007).
295. Hasmim M., Bieler G., Rüegg C.: Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J. Thromb. Haemost. 5(1), 166, (2007).
296. Bogatcheva N.V., Adyshev D., Mambetsariev B., Moldobaeva N., Verin A.D.: Involvement of microtubules, p38, and Rho kinases pathway in 2-methoxyestradiol-induced lung vascular barrier dysfunction. Am. J. Physiol. Lung Cell Mol. Physiol. 292(2), L487, (2007).
297. Zhao M., Discipio R.G., Wimmer A.G., Schraufstatter I.U.: Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2. Mol. Pharmacol. 69(1), 66, (2006).
298. Yang C., Liu Y., Lemmon M.A., Kazanietz M.G.: Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol. Cell Biol. 26(3), 831, (2006).
299. Valderrama F., Cordeiro J.V., Schleich S., Frischknecht F., Way M.: Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling. Science 311(5759), 377, (2006).
300. Sumimoto H., Hirata K., Yamagata S., Miyoshi H., Miyagishi M., Taira K., Kawakami Y.: Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int. J. Cancer 118(2), 472, (2006).
301. Song S.H., Lee J.K., Hur J.Y., Kim I., Saw H.S., Park Y.K.: The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins. Int. J. Gynecol. Cancer 16(6), 2009, (2006).
302. Riganti C., Orecchia S., Pescarmona G., Betta P.G., Ghigo D., Bosia A.: Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int. J. Cancer 119(1), 17, (2006).
303. Palmi C., Fazio G., Cassetti A., Aloisi A., Villa A., Biondi A., Cazzaniga G.: TEL/ARG induces cytoskeletal abnormalities in 293T cells. Cancer Lett. 241(1), 79, (2006).
304. Mizukami Y., Fujiki K., Duerr E.-M., Gala M., Jo W.-S., Zhang X., Chung D.C.: Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J. Biol. Chem. 281(20), 13957, (2006).
305. Liu H., Radisky D.C., Nelson C.M., Zhang H., Fata J.E., Roth R.A., Bissell M.J.: Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc. Natl. Acad. Sci. USA 103(11), 4134, (2006).
306. Lawler K., Foran E., O'Sullivan G., Long A., Kenny D.: Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am. J. Physiol. Cell Physiol. 291(4), C668, (2006).
307. Kühlewein C., Rechner C., Meyer T.F., Rudel T.: Low-phosphate- dependent invasion resembles a general way for Neisseria gonorrhoeae to enter host cells. Infect. Immun. 74(7), 4266, (2006).
308. Gong Y., Sohn H., Xue L., Firestone G.L., Bjeldanes L.F.: 3,3′-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res. 66(9), 4880, (2006).
309. Fryer B.H., Wang C., Vedantam S., Zhou G.-L., Jin S., Fletcher L., Simon M.C., Field J.: cGMP-dependent protein kinase phosphorylates p21-activated kinase (Pak) 1, inhibiting Pak/Nck binding and stimulating Pak/vasodilator- stimulated phosphoprotein association. J. Biol. Chem. 281(17), 11487, (2006).
310. Carragher N.O., Walker S.M., Scott C.L.A., Harris F., Sawyer T.K., Brunton V.G., Ozanne B.W., Frame M.C.: Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function. Oncogene 25(42), 5726, (2006).
311. Bartolomé R.A., Molina-Ortiz I., Samaniego R., Sánchez-Mateos P., Bustelo X.R., Teixidó J.: Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res. 66(1), 248, (2006).
312. Barber M.A., Welch H.C.E.: PI3K and RAC signalling in leukocyte and cancer cell migration. Bull. Cancer 93(5), E44, (2006).
313. Yamaguchi T., Goto H., Yokoyama T., Silljé H., Hanisch A., Uldschmid A., Takai Y., Oguri T., et al.: Phosphorylation by Cdk1 induces Plk1-mediated vimentin phosphorylation during mitosis. J. Cell Biol. 171(3), 431, (2005).
314. Nguyen Q.-D., De W.O., Bruyneel E., Hendrix A., Xie W.-Z., Lombet A., Leibl M., Mareel M., et al.: Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene 24(56), 8240, (2005).
315. Han S., Sidell N., Roman J.: Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett. 219(1), 71, (2005).
316. Cardone R.A., Bagorda A., Bellizzi A., Busco G., Guerra L., Paradiso A., Casavola V., Zaccolo M., et al.: Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol. Biol. Cell 16(7), 3117, (2005).
317. Wang D.-S., Dou K.-F., Li K.-Z., Song Z.-S.: Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J. Gastroenterol. 10(2), 299, (2004).
318. Lee J.-S., Kamijo K., Ohara N., Kitamura T., Miki T.: MgcRacGAP regulates cortical activity through RhoA during cytokinesis. Exp. Cell Res. 293(2), 275, (2004).
319. Brown K., Bhowmick N.A.: Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle 3(4), 408, (2004).
320. Suyama E., Kawasaki H., Kasaoka T., Taira K.: Identification of genes responsible for cell migration by a library of randomized ribozymes. Cancer Res. 63(1), 119, (2003).
321. Saurin J.-C., Fallavier M., Sordat B., Gevrey J.-C., Chayvialle J.-A., Abello J.: Bombesin stimulates invasion and migration of Isreco1 colon carcinoma cells in a Rho-dependent manner. Cancer Res. 62(16), 4829, (2002).
322. Arthur W.T., Ellerbroek S.M., Der C.J., Burridge K., Wennerberg K.: XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J. Biol. Chem. 277(45), 42964, (2002).
323. Matsumoto Y., Tanaka K., Harimaya K., Nakatani F., Matsuda S., Iwamoto Y.: Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn. J. Cancer Res. 92(4), 429, (2001).
324. Somlyo A.V., Bradshaw D., Ramos S., Murphy C., Myers C.E., Somlyo A.P.: Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 269(3), 652, (2000).
325. Kosako H., Yoshida T., Matsumura F., Ishizaki T., Narumiya S., Inagaki M.: Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. Oncogene 19(52), 6059, (2000).
326. Oi K., Shimokawa H., Hiroki J., Uwatoku T., Abe K., Matsumoto Y., Nakajima Y., Nakajima K., et al.: Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler. Thromb. Vasc. Biol. 24(5), 918, (2004).
327. Xu Z., Okamoto H., Akino M., Onozuka H., Matsui Y., Tsutsui H.: Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J. Cardiovasc. Pharmacol. 51(1), 62, (2008).
328. Fukui S., Fukumoto Y., SuzukiJ., Saji K., Nawata J., Tawara S., Shinozaki T., Kagaya Y., et al.: Long-term Inhibition of Rho-kinase Ameliorates Diastolic Heart Failure in Hypertensive Rats. J. Cardiovasc. Pharmacol. 51(3), 317, (2008).
329. Gong K.Z., Song G., Spiers J.P., Kelso E.J., Zhang Z.G.: Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int. J. Clin. Pract. 61(4), 611, (2007).
330. Del Re D.P., Miyamoto S., Brown J.H.: RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J. Biol. Chem. 282(11), 8069, (2007).
331. Winaver J., Ovcharenko E., Rubinstein I., Gurbanov K., Pollesello P., Bishara B., Hoffman A., Abassi Z.: Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 290(5), H2007, (2006).
332. Koida S., Ohyanagi M., Ueda A., Mori Y., Iwasaka T.: Mechanism of increased alpha-adrenoceptor-mediated contraction in small resistance arteries of rats with heart failure. Clin. Exp. Pharmacol. Physiol. 33(1-2), 47, (2006).
333. Satoh S., Ueda Y., Koyanagi M., Kadokami T., Sugano M., Yoshikawa Y., Makino N.: Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J. Mol. Cell Cardiol. 35(1), 59, (2003).
334. Kobayashi N., Horinaka S., Mita S.-I., Nakano S., Honda T., Yoshida K., Kobayashi T., Matsuoka H.: Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc. Res. 55(4), 757, (2002).
335. Suematsu N., Satoh S., Kinugawa S., Tsutsui H., Hayashidani S., Nakamura R., Egashira K., Makino N., et al.: Alpha1-adrenoceptor-Gq-RhoA signaling is upregulated to increase myofibrillar Ca2+ sensitivity in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 281(2), H637, (2001).
336. Matsumoto T., Wada A., Tsutamoto T., Omura T., Yokohama H., Ohnishi M., Nakae I., Takahashi M., et al.: Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure. Am. J. Physiol. Heart Circ. Physiol. 276(6), H1935, (1999).
337. Chang J., Xie M., Shah V.R., Schneider M.D., Entman M.L., Wei L., Schwartz R.J.: Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc. Natl. Acad. Sci. USA 103(39), 14495, (2006).
338. Kishi T., Hirooka Y., Masumoto A., Ito K., Kimura Y., Inokuchi K., Tagawa T., Shimokawa H., et al.: Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 111(21), 2741, (2005).
339. Schmitt M., Gunaruwan P., Payne N., Taylor J., Lee L., Broadley A.J.M., Nightingale A.K., Cockcroft J.R., et al.: Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure. Arterioscler. Thromb. Vasc. Biol. 24(5), 911, (2004).
340. Kikuchi Y., Yamada M., Imakiire T., Kushiyama T., Higashi K., Hyodo N., Yamamoto K., Oda T., et al.: A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 192(3), 595, (2007).
341. Grisk O., Frauendorf T., Schlüter T., Klöting I., Kuttler B., Krebs A., Lüdemann J., Rettig R.: Impaired coronary function in Wistar Ottawa Karlsburg W rats-a new model of the metabolic syndrome. Pflugers Arch. 454(6), 1011, (2007).
342. Chang L., Chiang S.-H., Saltiel A.R.: TC10alpha is required for insulin-stimulated glucose uptake in adipocytes. Endocrinology 148(1), 27, (2007).
343. Lee J.H., Ragolia L.: AKT phosphorylation is essential for insulin-induced relaxation of rat vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 291(6), C1355, (2006).
344. Chiang S.-H., Chang L., Saltiel A.R.: TC10 and insulin-stimulated glucose transport. Methods Enzymol. 406, 701, (2006).
345. Pulinilkunnil T., An D., Ghosh S., Qi D., Kewalramani G., Yuen G., Virk N., Abrahani A., et al.: Lysophosphatidic acid-mediated augmentation of cardiomyocyte lipoprotein lipase involves actin cytoskeleton reorganization. Am. J. Physiol. Heart Circ. Physiol. 288(6), H2802, (2005).
346. Erdös B., Snipes J.A., Kis B., Miller A.W., Busija D.W.: Vasoconstrictor mechanisms in the cerebral circulation are unaffected by insulin resistance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287(6), R1456, (2004).
347. Begum N., Sandu O.A., Ito M., Lohmann S.M., Smolenski A.: Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J. Biol. Chem. 277(8), 6214, (2002).
348. Begum N., Sandu O.A., Duddy N.: Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways. Diabetes 51(7), 2256, (2002).
349. Sandu O.A., Ito M., Begum N.: Selected contribution: insulin utilizes NO/cGMP pathway to activate myosin phosphatase via Rho inhibition in vascular smooth muscle. J. Appl. Physiol. 91(3), 1475, (2001).
350. Sandu O.A., Ragolia L., Begum N.: Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 49(12), 2178, (2000).
351. Farah S., Agazie Y., Ohan N., Ngsee J.K., Liu X.J.: A rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. J. Biol. Chem. 273(8), 4740, (1998).
352. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Kaibuchi K., Takeshita A.: Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ. Res. 94(1), 46, (2004).
353. Mueed I., Tazzeo T., Liu C., Pertens E., Zhang Y., Cybulski I., Semelhago L., Noora J., et al.: Isoprostanes constrict human radial artery by stimulation of thromboxane receptors, Ca2+ release, and RhoA activation. J. Thorac. Cardiovasc. Surg. 135(1), 131, (2008).
354. Okon E.B., Millar M.J., Crowley C.M., Bashir J.G., Cook R.C., Hsiang Y.N., McManus B., van Breeman C.: Effect of moderate pressure distention on the human saphenous vein vasomotor function. Ann. Thorac. Surg. 77(1), 108, (2004).
355. Morikage N., Kishi H., Sato M., Guo F., Shirao S., Yano T., Soma M., Hamano K., et al.: Cholesterol primes vascular smooth muscle to induce Ca2 sensitization mediated by a sphingosylphosphorylcholine-Rho-kinase pathway: possible role for membrane raft. Circ. Res. 99(3), 299, (2006).
356. Zhu Y., Liao H.-L., Niu X.-L., Yuan Y., Lin T., Verna L., Stemerman M.B.: Low density lipoprotein induces eNOS translocation to membrane caveolae: the role of RhoA activation and stress fiber formation. Biochim. Biophys. Acta 1635(2-3), 117, (2003).
357. Furuyama T., Komori K., Shimokawa H., Matsumoto Y., Uwatoku T., Hirano K., Maehara Y.: Long-term inhibition of Rho kinase suppresses intimal thickening in autologous vein grafts in rabbits. J. Vasc. Surg. 43(6), 1249, (2006).
358. Chung A.W.Y., Rauniyar P., Luo H., Hsiang Y.N., van Breemen C., Okon E.B.: Pharmacologic relaxation of vein grafts is beneficial compared with pressure distention caused by upregulation of endothelial nitric oxide synthase and nitric oxide production. J. Thorac. Cardiovasc. Surg. 132(4), 925, (2006).
359. Chung A.W.Y., Rauniyar P., Luo H., Hsiang Y.N., van Breemen C., Okon E.B.: Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. J. Vasc. Surg. 42(4), 747, (2005).
360. Yamanouchi D., Banno H., Nakayama M., Sugimoto M., Fujita H., Kobayashi M., Kuwano H., Komori K.: Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J. Vasc. Surg. 42(4), 757, (2005).
361. Turner N.A., O'Regan D.J., Ball S.G., Porter K.E.: Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 19(7), 804, (2005).
362. Kozai T., Eto M., Yang Z., Shimokawa H., Lüscher T.F.: Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc. Res. 68(3), 475, (2005).
363. Crowley C.M., Lee C.-H., Gin S.A., Keep A.M., Cook R.C., van Breeman C.: The mechanism of excitation-contraction coupling in phenylephrine-stimulated human saphenous vein. Am. J. Physiol. Heart Circ. Physiol. 283(4), H1271, (2002).